Glioblastoma, IDH-Wildtype — Trials

Glioblastoma, IDH-Wildtype — Trials · CancerIndex

Clinical trials

Registered studies

303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 76
Recruiting: 42
Ph III recruiting: 3
Growth YoY: —
Industry share: 12%
Top sponsor: Mayo Clinic
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (64)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05017610	Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma	withdrawn	Early Phase 1	0	Emory UniversityOTHER	0	Dec 2, 2022	clinicaltrials

Data updated 22 days agoSource updated Dec 2, 2022source: clinicaltrials